Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

Partyflags Dec. 13 at 6:13 AM

$GOSS I reviewed the protocol update on http://ClinicalTrials.gov and saw that it has now been officially updated to state that the last patient has completed the 24-week treatment period. From here, the study moves into full data cleaning, and effectively the race to topline has begun. It is possible that a topline announcement could come as early as January — the timelines do allow for that.

1 · Reply

boomupwego Dec. 13 at 1:28 AM

$GOSS $NVCT $SGMO No thanks. I’ll stick with GOSS for now….

1 · Reply

MoneyGroupLLC Dec. 12 at 10:28 PM

Enter: $GOSS Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.20 - $0.25 Sell Price: $0.43 Profit : +116% (Turn every $1 into $2.16) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

mmtiddy Dec. 12 at 7:19 PM

$SGMO Sold my positions on $GOSS and $NVCT for this, $0.40 cents with their drugs on trial? I am autistic and I know this is completely undervalued to what the big dogs have been thinking

1 · Reply

MOOSEN Dec. 12 at 6:36 PM

$GOSS JUST PEEP THIS BEAST. CAN LIL’ OL’ ME COP A QUAD-BAGGER? SHOOOOR.

0 · Reply

boomupwego Dec. 12 at 3:28 PM

$GOSS what happens when a stock is rising faster than the algos like. Gotta keep that price suppressed or it’ll trigger an algo avalanche

0 · Reply

Finnish_boy Dec. 12 at 2:37 PM

$GOSS WEN 4?

1 · Reply

tomwalt Dec. 12 at 1:32 PM

$GOSS Too many bulls here

3 · Reply

Jaychris24 Dec. 12 at 1:08 AM

$GOSS @Sandeman52 take a peak. Been in on a bunch with you maybe you’ll like this.

0 · Reply

Finnish_boy Dec. 11 at 11:53 PM

$GOSS

0 · Reply

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 24, 2025, 4:01 PM EST - 18 days ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 5, 2025, 4:01 PM EST - 5 weeks ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Sep 25, 2025, 7:41 AM EDT - 2 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 22, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 9:50 AM EDT - 3 months ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Aug 29, 2025, 7:31 AM EDT - 3 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 5, 2025, 4:01 PM EDT - 4 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 16, 2025, 7:31 AM EDT - 6 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

May 15, 2025, 9:30 PM EDT - 7 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 12, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 7, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Mar 13, 2025, 4:01 PM EDT - 9 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 7:42 PM EST - 10 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 11 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 11 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Jan 30, 2023, 4:48 AM EST - 3 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Dec 8, 2022, 1:27 PM EST - 3 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 6, 2022, 8:19 AM EST - 3 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 7:15 AM EST - 3 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Partyflags Dec. 13 at 6:13 AM

1 · Reply

boomupwego Dec. 13 at 1:28 AM

$GOSS $NVCT $SGMO No thanks. I’ll stick with GOSS for now….

1 · Reply

MoneyGroupLLC Dec. 12 at 10:28 PM

0 · Reply

mmtiddy Dec. 12 at 7:19 PM

$SGMO Sold my positions on $GOSS and $NVCT for this, $0.40 cents with their drugs on trial? I am autistic and I know this is completely undervalued to what the big dogs have been thinking

1 · Reply

MOOSEN Dec. 12 at 6:36 PM

$GOSS JUST PEEP THIS BEAST. CAN LIL’ OL’ ME COP A QUAD-BAGGER? SHOOOOR.

0 · Reply

boomupwego Dec. 12 at 3:28 PM

$GOSS what happens when a stock is rising faster than the algos like. Gotta keep that price suppressed or it’ll trigger an algo avalanche

0 · Reply

Finnish_boy Dec. 12 at 2:37 PM

$GOSS WEN 4?

1 · Reply

tomwalt Dec. 12 at 1:32 PM

$GOSS Too many bulls here

3 · Reply

Jaychris24 Dec. 12 at 1:08 AM

$GOSS @Sandeman52 take a peak. Been in on a bunch with you maybe you’ll like this.

0 · Reply

Finnish_boy Dec. 11 at 11:53 PM

$GOSS

0 · Reply

StockScubaDiver Dec. 11 at 10:40 PM

$GOSS soon

0 · Reply

boomupwego Dec. 11 at 10:21 PM

$GOSS Just purchased another 14k shares in blocks of 5000 besides last one. Price jumped cause I chased the ask lol

1 · Reply

Zobzork Dec. 11 at 9:50 PM

$GOSS badaboum (im just anmoying that other guy for fun btw)

1 · Reply

SadyK189 Dec. 11 at 9:04 PM

Here is my Amazing daily Stocktwits report 1 / 2: $BEAT $ASTI $NBY $IRBT $GOSS BEAT: Price 1.34. My post last night "BEAT has maintained key support zone of 1.05 - 1.20. It can test 1.65 - 1.80 zone again. Currently at 1.34" It hit our desired zone, made a nice run to 2.79 ASTI Price 2.66. My post last night "Looking good on daily chart. Key support at 1.9 - 2.10. Next key level to test is 3.1 - 3.4" It went till 3.64 NBY: My post last night "NBY is trending nicely on daily chart. Key support at 1.75 - 1.90. Next key level to test is 2.70 - 2.80. Currently at 2.30" It went till 2.95 IRBT: Price 4.95. My post last night "Initially alerted at 3.30. Still looking good on daily chart. Key support at 3.70 - 4. Next key level to test is 5.75 - 6.10" It went till 6.04 today GOSS Price 3.20. My post was "GOSS is moving slowly and steadily but nicely on daily chart. Key support at 2.40 - 2.60. Next key level to test is 3.6 - 3.85. It may take sometime though" It went till 3.8 today

0 · Reply